Triple Therapy for the Management of COPD: A Review

REFERENCES

• Todd DC, McIvor RA, Pugsley SO, Cox G. Approach to chronic obstructive pulmonary disease in primary care. Can Fam Physician 2008 May; 54(5):706–711.
   PubMed Web of Science ®Google Scholar
• McIvor RA. Future options for disease intervention: Important advances in phosphodiesterase 4 inhibitors. Eur Respir Rev 2007; 16(105):105–112.
   Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997 May 24; 349(9064):1498–1504.
   PubMed Web of Science ®Google Scholar
• Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370(9589):741–750.
   PubMed Web of Science ®Google Scholar
• Caballero A, Torres-Duque CA, Jaramillo C, Bolivar F, Sanabria F, Osorio P, Orduz C, Guevara DP, Maldonado D. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest 2008;133(2):343–9.
   PubMed Web of Science ®Google Scholar
• Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, Pehlivan E. Prevalence of COPD: first epidemiological study of a large region in Turkey. Eur J Intern Med 2008; 19(7):499–504.
   PubMed Web of Science ®Google Scholar
• Methvin JN, Mannino DM, Casey BR. COPD prevalence in southeastern Kentucky: the burden of lung disease study. Chest 2009; 135(1):102–107.
   PubMed Web of Science ®Google Scholar
• van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, Joos GF, Stricker BH, Brusselle GG. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest 2009; 135(2):368–377.
   PubMed Web of Science ®Google Scholar
• Dales RE, Aaron SD, Vandemheen KL, Mehdizadeh A, Clinch J. The prevalence of airflow obstruction in rural primary care. Respir Med 2006; 100(4):754–759.
   PubMed Web of Science ®Google Scholar
• Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL, Heels-Ansdell DM, Erak M, Bragaglia PJ, Tamari IE, Hodder R, Stanbrook MB. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ 2010 April 20; 182(7):673–678.
   PubMed Web of Science ®Google Scholar
• Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, Crapo RO, Jensen RL, Burney PG. The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and design. COPD 2005 June; 2(2):277–283.
   PubMedGoogle Scholar
• Decramer M, Nici L, Nardini S, Reardon J, Rochester CL, Sanguinetti CM, Troosters T. Targeting the COPD exacerbation. Respir Med 2008 June; 102 Suppl 1:S3–15.
   PubMedGoogle Scholar
• Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010 June; 7(3):214–228.
   PubMedGoogle Scholar
• Oostenbrink JB, Rutten-Van Molken MPMH. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004; 98(9):883–891.
   PubMed Web of Science ®Google Scholar
• Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, Fitzgerald JM. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med 2008 March; 102(3):413–421.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Maltais F, Road J, McKay V, Schenkel J, Ariel A, Day A, Lacasse Y, Levy R, Lien D, Miller J, Rocker G, Sinuff T, Stewart P, Voduc N, Abboud R, Ariel A, Becklake M, Borycki E, Brooks D, Bryan S, Calcutt L, Chapman K, Choudry N, Couet A, Coyle S, Craig A, Crawford I, Dean M, Grossman R, Haffner J, Heyland D, Hogg D, Holroyde M, Kaplan A, Kayser J, Lein D, Lowry J, McDonald L, MacFarlane A, McIvor A, Rea J, Reid D, Rouleau M, Samis L, Sin D, Vandemheen K, Wedzicha JA, Weiss K. State of the art compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can Respir J 2004 July; 11 Suppl B:7–59B.
   PubMedGoogle Scholar
• McIvor RA. Tiotropium and chronic obstructive pulmonary disease. BMJ 2010; 340:c833.
   PubMedGoogle Scholar
• American Thoracic Society, European Thoracic Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168(7):818–900.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda (MD): National Heart, Lung and Blood Institute; 2008.
   Google Scholar
• O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Kaplan A, Keenan S, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can Respir J 2007; 14(Suppl B):5–32B.
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992 June; 145(6):1321–1327.
   PubMed Web of Science ®Google Scholar
• Quirk FH, Jones PW. Patients’ perception of distress due to symptoms and effects of asthma on daily living and an investigation of possible influential factors. Clin Sci (Lond) 1990 July; 79(1):17–21.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 February;17(1):1–12.
   PubMedGoogle Scholar
• Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002 February 16; 359(9306):614–618.
   PubMed Web of Science ®Google Scholar
• Fang LZ, Liang X, Zhang JQ, Liu L, Fu WP, Zhao ZH, Dai LM. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi 2008; 31(11):811–814.
   PubMedGoogle Scholar
• Cazzola M, Ando F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, D'Amato M. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007; 20(5):556–61.
   PubMed Web of Science ®Google Scholar
• Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in COPD patients. Am J Respir Crit Care Med 2009 August 13; 180:741–750.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M. Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146(8):545–555.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003 December; 22(6):931–936.
   PubMed Web of Science ®Google Scholar
• Andersson F, Borg S, Jansson S-A, Jonsson A-C, Ericsson A, Prutz C, Ronmark E, Lundback B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96(9):700–708.
   PubMed Web of Science ®Google Scholar
• Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002 March; 19(3):398–404.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 October 9; 359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Molken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008 February; 31(2):416–469.
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Lipson S, Miles TP, White L. Prospective study of pneumonia hospitalizations and mortality of U.S. older people: the role of chronic conditions, health behaviors, and nutritional status. Public Health Rep 1989 July; 104(4):350–360.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med 2009 February; 103(2):224–229.
   PubMed Web of Science ®Google Scholar
• O'Meara ES, White M, Siscovick DS, Lyles MF, Kuller LH. Hospitalization for pneumonia in the Cardiovascular Health Study: incidence, mortality, and influence on longer-term survival. J Am Geriatr Soc 2005 July; 53(7):1108–16.
   PubMed Web of Science ®Google Scholar